Debanjana Chatterjee
Stock Analyst at Jones Trading
(4.78)
# 748
Out of 5,182 analysts
20
Total ratings
81.25%
Success rate
38.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Maintains: Buy | $52 → $63 | $39.63 | +58.95% | 2 | Apr 28, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $64 → $95 | $69.74 | +36.22% | 3 | Apr 17, 2026 | |
| HYFT MindWalk Holdings | Initiates: Buy | $5 | $1.22 | +311.52% | 1 | Apr 16, 2026 | |
| ABCL AbCellera Biologics | Initiates: Buy | $11 | $4.19 | +162.53% | 1 | Apr 10, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $25 → $24 | $13.63 | +76.08% | 1 | Mar 19, 2026 | |
| NTLA Intellia Therapeutics | Upgrades: Buy | $29 | $13.23 | +119.20% | 3 | Mar 4, 2026 | |
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $9.65 | +55.44% | 1 | Jan 5, 2026 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $16.62 | +44.40% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $8.52 | +216.90% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $3.18 | +1,125.88% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 | $19.07 | +57.32% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $12.37 | +85.93% | 1 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $28.24 | +62.89% | 1 | Sep 19, 2024 |
Sionna Therapeutics
Apr 28, 2026
Maintains: Buy
Price Target: $52 → $63
Current: $39.63
Upside: +58.95%
Spyre Therapeutics
Apr 17, 2026
Maintains: Buy
Price Target: $64 → $95
Current: $69.74
Upside: +36.22%
MindWalk Holdings
Apr 16, 2026
Initiates: Buy
Price Target: $5
Current: $1.22
Upside: +311.52%
AbCellera Biologics
Apr 10, 2026
Initiates: Buy
Price Target: $11
Current: $4.19
Upside: +162.53%
Trevi Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $24
Current: $13.63
Upside: +76.08%
Intellia Therapeutics
Mar 4, 2026
Upgrades: Buy
Price Target: $29
Current: $13.23
Upside: +119.20%
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $9.65
Upside: +55.44%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $16.62
Upside: +44.40%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $8.52
Upside: +216.90%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $3.18
Upside: +1,125.88%
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $19.07
Upside: +57.32%
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $12.37
Upside: +85.93%
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $28.24
Upside: +62.89%